In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
In other recent news, Recursion Pharmaceuticals reported its fourth-quarter 2025 earnings, delivering results that surpassed expectations. The company posted an earnings per share (EPS) of -$0.21, ...
JDK 26 moves to general production availability. This short-term release is backed by six months of Premier-level support. Java Development Kit (JDK) 26, the latest standard Java release from Oracle, ...
Nvidia's recent $700 million acquisition of Run:ai enhances GPU access and infrastructure flexibility. The acquisition of OctoAI for $250 million bolsters Nvidia's generative AI tools portfolio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results